Crossmark

A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution

Crossref DOI link: https://doi.org/10.1007/s12185-025-04130-w

Published Online: 2025-12-16

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hattori, Keiichiro

Kurita, Naoki

Matsumura, Fumiaki

Makishima, Kenichi

Suma, Sakurako

Sasaki, Yuya

Suehara, Yasuhito

Maruyama, Yumiko

Sakamoto, Tatsuhiro

Kato, Takayasu

Nishikii, Hidekazu

Sugii, Narushi

Matsuda, Masahide

Ishikawa, Eiichi

Obara, Naoshi

Sakata-Yanagimoto, Mamiko https://orcid.org/0000-0001-7310-8045
License Information

Text and Data Mining valid from 2025-12-16

Version of Record valid from 2025-12-16
More Information

Article History

Received: 11 May 2025

Revised: 2 December 2025

Accepted: 2 December 2025

First Online: 16 December 2025

Declarations

:

: Research fund: Sakata-Yanagimoto Mamiko (Eisai, Bristol Myers Squib, Otuska Pharma, Chugai Pharma). The authors declare no competing interests.

: The study was approved by the institutional review board of University of Tsukuba Hospital (approval R06-28).

: Opt-out information was prominently displayed on the web page of University of Tsukuba Hospital.

Document is current

Any future updates will be listed below